# Webinar: Achieving Diversity and Inclusion in Clinical Trials

> Cassandra Smith of Janssen looks at the lack of clinical trial diversity in drug development and how sponsors can improve accessibility for greater inclusion.

**Published:** Jun 30, 2020  
**Updated:** Aug 28, 2024

---

Clinical trials should be accessible to the population suffering from the illness. However, underrepresentation in clinical trials by racial and ethnic minorities continues to be a multi-layered problem.

Cassandra Smith, Director of Diversity and Inclusion in Clinical Trials Lead, Janssen R&D looks at why a changing global population requires more clinical trial diversity for the future of drug development and what role sponsors can play to make trials more accessible to all patients.

*Video: Webinar: Achieving Diversity and Inclusion in Clinical Trials*

Cassandra originally presented this segment in a longer webinar addressing clinical trial inclusion and diversity titled "_No One Left Behind: Addressing Clinical Trial Access and Issues Blocking Physician Participation_."